BRPI0516803A - oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos - Google Patents

oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos

Info

Publication number
BRPI0516803A
BRPI0516803A BRPI0516803-1A BRPI0516803A BRPI0516803A BR PI0516803 A BRPI0516803 A BR PI0516803A BR PI0516803 A BRPI0516803 A BR PI0516803A BR PI0516803 A BRPI0516803 A BR PI0516803A
Authority
BR
Brazil
Prior art keywords
oxylipines
dpan
production
derived
long chain
Prior art date
Application number
BRPI0516803-1A
Other languages
English (en)
Inventor
Linda Mary Arterburn
James Flatt
Jung Lee
Elswyk Mary Van
William Barclay
Bindi Dangi
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Publication of BRPI0516803A publication Critical patent/BRPI0516803A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6434—Docosahexenoic acids [DHA]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

OXILIPINAS DE áCIDOS GRAXOS POLINSATURADOS DE CADEIA LONGA E MéTODOS DE PRODUçãO E USO DOS MESMOS. Onde são reveladas novas oxilipinas, referidas aqui como docosanóides, que são derivados dos ácidos graxos polinsaturados e método de produzir e usar estas oxilipinas. Também é revelado o uso do ácido docosapentaenóico (C22:5n-6) (DPAn-6), ácido docosapentaenóico (C22:5n-3) (DPAn-3) e ácido docosatetraenóico (DTAn-6 C22:4n-6) como substratos para a produção de novas oxilipinas e oxilipinas produzidas destas. Ainda é revelado o uso de DPAn-6, DPAn-3, DTAn-6 e/ou oxilipinas derivadas destes e/ou novos docosanóides derivados das estruturas dos ácidos graxos C22, nas aplicações terapêuticas e nutricionais ou cosméticas e, particularmente, como compostos antiinflamatórios ou anti-neurodegenerativos. A invenção também se refere a novos meios de produzir óleos ricos em ácidos polinsaturados de cadeia longa (LCPUFA) e composições que contenham quantias maiores e efetivas de oxilipinas derivadas de LCPUFA e, particularmente, docosanóides.
BRPI0516803-1A 2004-11-19 2005-11-21 oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos BRPI0516803A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62984204P 2004-11-19 2004-11-19
US72903805P 2005-10-21 2005-10-21
PCT/US2005/042462 WO2006055965A2 (en) 2004-11-19 2005-11-21 Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Publications (1)

Publication Number Publication Date
BRPI0516803A true BRPI0516803A (pt) 2008-09-23

Family

ID=36407879

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516803-1A BRPI0516803A (pt) 2004-11-19 2005-11-21 oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos

Country Status (13)

Country Link
US (2) US7884131B2 (pt)
EP (1) EP1824809A4 (pt)
JP (1) JP2008520739A (pt)
KR (1) KR20070090928A (pt)
CN (1) CN101102988B (pt)
AU (1) AU2005306320B2 (pt)
BR (1) BRPI0516803A (pt)
CA (1) CA2588166A1 (pt)
EA (1) EA010802B1 (pt)
IL (1) IL183246A0 (pt)
MX (1) MX2007006049A (pt)
NZ (1) NZ555394A (pt)
WO (1) WO2006055965A2 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
BRPI0613358A8 (pt) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
WO2007041440A2 (en) * 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
US20090320148A1 (en) * 2006-01-31 2009-12-24 Martek Biosciences Corporation Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
CA2650607A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
MX2009000657A (es) * 2006-07-19 2009-05-28 Resolvyx Pharmaceuticals Inc Composiciones y metodos para el tratamiento de mucositis.
WO2008057283A2 (en) * 2006-10-26 2008-05-15 Resolvyx Pharmaceuticals, Inc. Use of resolvins for inhibition of bone loss
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
WO2008103753A2 (en) * 2007-02-20 2008-08-28 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
RU2009139002A (ru) * 2007-03-23 2011-04-27 Новартис АГ (CH) Применение замаскированной или с нанесенным на нее покрытием соли меди для лечения дегенерации желтого пятна
US20100159540A1 (en) * 2007-03-26 2010-06-24 Ana Rodriguez Synthesis of resolvins and intermediates, compounds prepared thereby, and uses thereof
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
CA2699483A1 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Compositions and methods for modulating immune function
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
WO2009086281A1 (en) * 2007-12-21 2009-07-09 Martek Biosciences Corporation Method for preparation of oxylipins
JP2011519373A (ja) 2008-05-01 2011-07-07 コンプレクザ インコーポレイテッド ビニル置換脂肪酸
EP2299997A4 (en) 2008-06-19 2012-01-11 Univ Utah Res Found USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2344441B1 (en) * 2008-09-16 2016-02-17 The Brigham And Women's Hospital Inc. 7,14-dihydroxy-docosahexaenoic acid compounds
JP6113954B2 (ja) * 2008-10-31 2017-04-12 リピッド ファーマシューティカルズ イーエイチエフ． 医薬として使用するための脂肪酸
WO2010095706A1 (ja) * 2009-02-20 2010-08-26 国立大学法人東京大学 新規抗炎症性化合物
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
DK2429317T4 (da) * 2009-04-17 2019-05-13 Natac Pharma S L Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
EP3045167A1 (en) 2009-07-31 2016-07-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Keto fatty acids as anti-inflammatory agents
WO2011028689A1 (en) 2009-09-01 2011-03-10 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
EP2483233A4 (en) 2009-10-02 2013-08-14 Complexa Inc HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
US10052299B2 (en) 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
JP5909183B2 (ja) * 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
WO2012026106A1 (ja) * 2010-08-25 2012-03-01 国立大学法人 東京大学 光学活性な新規抗炎症性化合物及びその製造方法
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012148930A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
KR102112087B1 (ko) 2011-04-26 2020-05-18 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
JP6145087B2 (ja) 2011-04-26 2017-06-07 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ酸化関与障害
JP6106157B2 (ja) 2011-04-26 2017-03-29 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． 神経変性障害および筋疾患に関与するｐｕｆａ
US9416118B2 (en) * 2011-06-10 2016-08-16 The Brigham And Women's Hospital, Inc. Docosahexaenoyl ethanolamides
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
US10322118B2 (en) * 2012-04-10 2019-06-18 Trustees Of Dartmouth College Compounds and methods for inhibiting Cif virulence factor
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
HK1211867A1 (en) 2012-08-24 2016-06-03 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
WO2014110261A1 (en) * 2013-01-11 2014-07-17 Massachusetts Eye And Ear Infirmary Cyp450 lipid metabolites reduce inflammation and angiogenesis
WO2014130894A1 (en) * 2013-02-21 2014-08-28 University Of Southern California Compositions for the treatment of inflammatory diseases
CA2905671A1 (en) * 2013-03-13 2014-09-18 Matinas Biopharma Inc. Omega-3 pentaenoic acid compositions and methods of use
EP3892608B1 (en) 2013-05-30 2025-07-23 The Brigham and Women's Hospital, Inc. Novel n-3 immunoresolvents: structures and actions
AU2016219517B2 (en) * 2015-02-09 2020-02-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
PT3865484T (pt) 2015-07-07 2024-01-30 H Lundbeck As Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas
HK1256301A1 (zh) * 2015-07-20 2019-09-20 The Brigham And Women's Hospital, Inc. 提高阿托伐他汀和清除感染的新的 13 系列消退素的说明
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
WO2017059451A1 (en) 2015-10-02 2017-04-06 Complexa, Inc. Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
WO2017083167A1 (en) 2015-11-10 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
EP3950649A1 (en) 2015-11-23 2022-02-09 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
WO2019104315A1 (en) * 2017-11-27 2019-05-31 Brown University Compositions and methods using lipids for treating neurological disease
WO2019104311A1 (en) * 2017-11-27 2019-05-31 Brown University Compositions and methods for suppressing neurological disease
EP3792351A4 (en) 2018-04-16 2022-01-19 Korea Research Institute of Bioscience and Biotechnology Method for producing multi-hydroxy derivatives of polyunsaturated fatty acids
CA3100988A1 (en) 2018-05-25 2019-11-28 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
CA3110680A1 (en) 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
KR102673270B1 (ko) * 2018-10-15 2024-06-07 (주)아모레퍼시픽 피부장벽 강화용 조성물
KR102704402B1 (ko) 2018-10-24 2024-09-06 (주)아모레퍼시픽 피부장벽 강화용 조성물
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
IL295783B2 (en) 2020-02-21 2026-03-01 Retrotope Inc Processes for isotopic alteration of polyunsaturated fatty acids and their derivatives
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
KR20220159751A (ko) 2021-05-26 2022-12-05 (주)아모레퍼시픽 미백용 조성물 및 이를 이용한 피부 미백방법
WO2024229108A1 (en) * 2023-05-01 2024-11-07 The Regents Of The University Of California In-situ production of anti-inflammatory lipids using milk fat globules

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63238075A (ja) * 1987-03-24 1988-10-04 Mitsumaru Kagaku Kk 高度不飽和脂肪酸からのラクトン類の製造法
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5102670A (en) 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
JPH05286956A (ja) * 1992-04-06 1993-11-02 Nippon Suisan Kaisha Ltd ドコサペンタエン酸モノエポキシ体、及びその製造法
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
CZ281096B6 (cs) * 1994-06-30 1996-06-12 Jindřich Mudr. Drsc. Mourek Tuková složka mléčné výživy a dětská výživa
US5955496A (en) 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
CN1109543C (zh) 1996-10-11 2003-05-28 斯卡里斯塔有限公司 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
US6174695B1 (en) 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
DE19757414A1 (de) 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
JPH11209259A (ja) * 1998-01-20 1999-08-03 Noevir Co Ltd 皮膚化粧料
CA2362515C (en) 1999-03-04 2008-07-15 Suntory Limited Utilization of material containing docosapentaenoic acid
JP4474082B2 (ja) 1999-07-07 2010-06-02 キリン協和フーズ株式会社 水酸化脂肪酸およびδ−ラクトン類の製造方法
HK1045985B (en) 1999-11-09 2004-04-23 Alcon, Inc. 15-hydroxyeicosatetraenoic acid-related compounds and methods of use
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
DE10046541A1 (de) 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
WO2002029018A2 (en) 2000-10-06 2002-04-11 Michigan State University Divinyl ether synthase gene and protein, and uses thereof
AU2002309856B2 (en) * 2001-05-14 2008-10-23 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
WO2003053423A2 (en) * 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US7527935B2 (en) 2002-03-19 2009-05-05 Mitsubishi Tanabe Pharma Corporation G-protein coupled receptor having eicosanoid as ligand and gene thereof
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
AU2003260687A1 (en) 2002-04-01 2003-10-20 University Of Southern California Trihydroxy polyunsaturated eicosanoids
FR2843124B1 (fr) 2002-08-02 2004-10-15 Goemar Lab Sa Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation
DE60330154D1 (de) * 2002-08-12 2009-12-31 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
US20040166130A1 (en) 2002-12-23 2004-08-26 L'oreal Lanolin-free cosmetic composition comprising a hydroxylated fatty acid aromatic ester
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same

Also Published As

Publication number Publication date
US7884131B2 (en) 2011-02-08
US20110178047A1 (en) 2011-07-21
KR20070090928A (ko) 2007-09-06
AU2005306320B2 (en) 2011-09-08
JP2008520739A (ja) 2008-06-19
AU2005306320A1 (en) 2006-05-26
WO2006055965A3 (en) 2006-11-30
CA2588166A1 (en) 2006-05-26
MX2007006049A (es) 2007-07-24
WO2006055965A2 (en) 2006-05-26
EP1824809A2 (en) 2007-08-29
EA200701100A1 (ru) 2007-10-26
EA010802B1 (ru) 2008-12-30
IL183246A0 (en) 2007-08-19
NZ555394A (en) 2010-07-30
CN101102988A (zh) 2008-01-09
US20060241088A1 (en) 2006-10-26
EP1824809A4 (en) 2010-03-03
CN101102988B (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
BRPI0516803A (pt) oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
WO2008036353A3 (en) Omega-3 diglyceride emulsions
NO20090692L (no) Farmasoytiske og kostholdsprodukter som omfatter vitamin K2
DE60138602D1 (de) Öl, das langkettige, mehrfach ungesättigte Fettsäuren aus Biomassen enthält, Verfahren zur Herstellung, Lebensmittel, Nahrungsmittelzusammensetzung, kosmetische oder pharmazeutische Zusammensetzung, die dieses enthält
SE8405308D0 (sv) Farmaceutisk komposition och forfarande for framstellning av densamma
ATE18572T1 (de) Nahrhafte zusammensetzungen, und verfahren zu ihrer herstellung.
EA201000400A1 (ru) Твердые жировые композиции, содержащие полиненасыщенные жирные кислоты, и способы их получения и использования
BR0106178A (pt) Processo para produção de ésteres de ácidos graxos de esteróis dietéticos
WO2004101757A3 (en) Production of polyunsaturated fatty acids in oleaginous yeasts
ATE542892T1 (de) Delta-17-desaturasen und ihre verwendung bei der herstellung von mehrfach ungesättigten fettsäuren
EP1549133A4 (en) FATTY SEEDSATURASES OF MUSHROOMS
PT996732E (pt) Metodos e composicoes para sintese de acidos gordos polinsaturados de cadeia longa em plantas
ATE474903T1 (de) Verfahren zum erhalt eines triglyceridreichen raffinierten avocadoöls und nach einem derartigen verfahren erhältliches öl
BRPI0413786A (pt) ácido graxo dessaturases de primula
WO2008129358A8 (en) Oil producing microbes and methods of modification thereof
EP2506848A4 (en) SUBSTANCES TO REDUCE THE IMPACT OF HARD CARDIAL EVENTS CONTAINING AN EXTRACT OF RED FERMENTED RICE AND A MULTIPLE UNSATURATED OMEGA-3 FATTY ACID OR DERIVATIVES THEREOF
RU2018110375A (ru) Композиции из рафинированного масла и способы их изготовления
WO2007090162A3 (en) OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
DE602004019884D1 (de) Zubereitungen enthaltend mehrfach ungesättigte phospholipide, monoterpene und tryptophan und/oder phytol-derivate
Patil Recent trends in production of polyunsaturated fatty acids (PUFA) concentrates
RU2006103799A (ru) Средство улучшения основного вкуса пищевого продукта, содержащее разложенные вещества высоконенасыщенной длинноцепьевой жирной кислоты или их экстракты
Chen et al. Global optimization for simultaneous extraction of oil and polysaccharides from Schizochytrium limacinum by enzyme‐assisted three‐phase partitioning
JP2020050882A (ja) 水産物由来遊離１価不飽和脂肪酸又はその低級アルコールエステルの製造方法
CN105886492A (zh) 一种固定化脂肪酶及其制备方法和在催化合成甘油酯型pufa中的应用
SE9903915D0 (sv) Kolesterolsänkande och blodfettsänkande komposition

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.